Trial Profile
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 21 May 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
- 11 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.